Meningococcal Meningitis Vaccine

Definition

The meningococcal meningitis vaccine is given by injection (shots) to provide immunization against meningococcal disease and meningitis caused by the bacterium Neisseria meningitides.

Description

Meningococcal disease, or meningococcemia, isa leading cause of meningitis in children, and then disease can also lead to infections of the blood. People who acquire the disease can become very ill, especially the young children. Meningococcal disease is treated with antibiotics, and the vaccine is not routinely recommended for most people in the United States. Particularly, it is not for children under age two, except under special circumstances.

Meningococcal meningitis is different from the meningitis in infants for which vaccination is routinely given. Before the 1990s, Haemophilus influenzae type b (Hib) was the leading cause of bacterial meningitis. However, vaccines given to all children as part of their routine immunization have reduced the frequency of the invasive diseases caused by H. influenzae and Streptococcus pneumonia, leaving neisseria meningitis as one of the leading causes of bacterial meningitis.

The meningococcal vaccine contains inactivated bacteria and cannot cause the disease. It is effective against four of the five subtypes of meningococcal meningitis. It is a one-time injection (except for the very young), and the effects last for four to five years. Adverse reactions are uncommon with this vaccine. Localized redness at the injection site lasting one or two days may occur. Less likely is an allergic reaction to the vaccine.

General use

Meningococcal vaccine is recommended for children and young adults as follows:

  • children two years old and older in a population where an outbreak has occurred
  • college students who live in close quarters (dormitories), who consume alcohol, smoke, or are regularly around smokers
  • those with certain chronic conditions, including those with spleen damage or immune disease
  • anyone traveling to or living in a part of the world where meningococcal disease is common, such as West Africa
  • household or institutional members who have contact with anyone with meningococcal disease (The same individuals should also receive prophylaxis antibiotic therapy.)
  • medical and laboratory personnel at risk of exposure to meningococcal disease

Advertisement
Advertisement